Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
27 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Western Equine Encephalitis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Western Equine Encephalitis - Pipeline Review, H2 2014', provides an overview of the Western Equine Encephalitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Western Equine Encephalitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Western Equine Encephalitis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Western Equine Encephalitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Western Equine Encephalitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Western Equine Encephalitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Western Equine Encephalitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Western Equine Encephalitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Western Equine Encephalitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Introduction 4 Global Markets Direct Report Coverage 4 Western Equine Encephalitis Overview 5 Therapeutics Development 6 Pipeline Products for Western Equine Encephalitis - Overview 6 Pipeline Products for Western Equine Encephalitis - Comparative Analysis 7 Western Equine Encephalitis - Therapeutics under Development by Companies 8 Western Equine Encephalitis - Pipeline Products Glance 9 Early Stage Products 9 Western Equine Encephalitis - Products under Development by Companies 10 Western Equine Encephalitis - Companies Involved in Therapeutics Development 11 Akshaya Bio Inc. 11 AlphaVax, Inc. 12 AltraVax Inc. 13 EpiVax, Inc. 14 Profectus BioSciences, Inc. 15 Western Equine Encephalitis - Therapeutics Assessment 16 Assessment by Monotherapy Products 16 Assessment by Target 17 Assessment by Molecule Type 18 Drug Profiles 20 equine encephalitis vaccine - Drug Profile 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 equine encephalitis vaccine - Drug Profile 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 equine encephalitis vaccine - Drug Profile 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 equine encephalitis vaccine - Drug Profile 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Westrern Equine Encephalitis Virus Vaccine - Drug Profile 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Western Equine Encephalitis - Dormant Projects 25 Appendix 26 Methodology 26 Coverage 26 Secondary Research 26 Primary Research 26 Expert Panel Validation 26 Contact Us 27 Disclaimer 27
List of Tables Number of Products under Development for Western Equine Encephalitis, H2 2014 6 Number of Products under Development for Western Equine Encephalitis - Comparative Analysis, H2 2014 7 Number of Products under Development by Companies, H2 2014 8 Comparative Analysis by Early Stage Development, H2 2014 9 Products under Development by Companies, H2 2014 10 Western Equine Encephalitis - Pipeline by Akshaya Bio Inc., H2 2014 11 Western Equine Encephalitis - Pipeline by AlphaVax, Inc., H2 2014 12 Western Equine Encephalitis - Pipeline by AltraVax Inc., H2 2014 13 Western Equine Encephalitis - Pipeline by EpiVax, Inc., H2 2014 14 Western Equine Encephalitis - Pipeline by Profectus BioSciences, Inc., H2 2014 15 Assessment by Monotherapy Products, H2 2014 16 Number of Products by Stage and Target, H2 2014 17 Number of Products by Stage and Molecule Type, H2 2014 19 Western Equine Encephalitis - Dormant Projects, H2 2014 25
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.